Related Experiment Video

Updated: May 11, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine

Parwathy Chandran1, Neha Gupta, Archana Payickattu Retnakumari

  • 1Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.

Nanomedicine : Nanotechnology, Biology, and Medicine
|May 15, 2013
PubMed

Insights

This study developed a novel polymer-protein nanomedicine to target and inhibit key kinases in Acute Myeloid Leukemia (AML) cells. The targeted nanomedicine demonstrated synergistic lethality against cancer cells while sparing healthy cells, offering a more specific and tolerable therapeutic approach.

Area of Science:

  • Biomedical Engineering
  • Nanomedicine
  • Cancer Therapeutics

Background:

  • Acute Myeloid Leukemia (AML) is characterized by deregulated kinome activity.
  • Current AML treatments can lack specificity and tolerability.

Purpose of the Study:

  • To develop a polymer-protein core-shell nanomedicine for simultaneous inhibition of key pro-survival kinases (mTOR, MAPK, STAT5) in AML.
  • To enhance targeted delivery and cellular uptake in primitive AML cells.

Main Methods:

  • Fabrication of a core-shell nanomedicine with loaded kinase inhibitors (everolimus, sorafenib).
  • Surface conjugation with anti-CD33 monoclonal antibody for targeted delivery.
  • Characterization using electron microscopy, flow cytometry, and confocal microscopy.
  • Evaluation of efficacy through immunoblotting, cytotoxicity, and apoptosis assays.

Main Results:

  • Confirmed formation of core-shell nanostructures (~290 nm) with enhanced cellular uptake.
  • Demonstrated synergistic lethality against AML cells via simultaneous kinase inhibition.
  • Showed preservation of healthy blood cells, indicating improved specificity.
  • Outperformed current clinical regimes (cytarabine and daunorubicin) in specificity and tolerability.

Conclusions:

  • The developed nanomedicine offers a promising, targeted approach for AML treatment.
  • Simultaneous multi-kinase inhibition via nanomedicine provides a synergistic and tolerable therapeutic strategy.
  • This advanced nanomedicine has potential for future clinical application in AML therapy.
Keywords:
Cancer kinomeCore-shell nanomedicineKinase inhibitorsLeukemiaTargeting

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...